Stock Price Prediction

RANI stock has a bullish outlook with analysts maintaining a "Buy" rating and a price target of $8.00, representing a significant upside from its current price of $2.27. This optimism is driven by promising preclinical data for its GLP-1 incretin triagonist and plans for a Phase 1 study in 2025, alongside improved financials with reduced losses. Additionally, insider purchases and institutional interest further support confidence in the stock's potential.

RANI stock currently trades at $2.27, significantly below analysts' price targets of $8.00 and $12.25, reflecting a potential upside of over 250%. However, mixed insider and institutional activity, alongside a recent $12.7M quarterly loss, suggests cautious optimism as the company focuses on advancing its RaniPill® platform and upcoming clinical trials.